Results 1 to 10 of about 39,176 (275)

Infections associated with clozapine: a pharmacovigilance study using VigiBase®

open access: yesFrontiers in Pharmacology, 2023
Introduction: Clozapine is primarily reserved for treatment-resistant schizophrenia due to safety concerns associated with its use. Infections have been reported with clozapine, which may lead to elevated serum levels of the drug.
Basile Chrétien   +11 more
doaj   +1 more source

An evaluation of the variation and underuse of clozapine in the United Kingdom [PDF]

open access: yes, 2021
Background Clozapine is the only licensed treatment for treatment refractory schizophrenia. Despite this, it remains grossly underused relative to the prevalence of refractory schizophrenia.
Sukhwinder S. Shergill   +5 more
core   +1 more source

sj-jpeg-1-tpp-10.1177_20451253211072341 – Supplemental material for Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study

open access: yes, 2022
Supplemental material, sj-jpeg-1-tpp-10.1177_20451253211072341 for Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study by Claas-Frederik Johannsen, Tonny Studsgaard Petersen, Jimmi Nielsen ...
Anders Fink-Jensen (724822)   +5 more
core   +1 more source

Reasons for admission to a general medical hospital for patients taking clozapine

open access: yesTherapeutic Advances in Psychopharmacology, 2022
Background: Clozapine is associated with a diverse range of side effects. In addition, patients prescribed clozapine commonly suffer with medical comorbidities.
Siobhan Gee   +4 more
doaj   +1 more source

Patterns of clozapine use, misuse and disuse in a mental health area in southern Spain

open access: yesEuropean Psychiatry, 2022
Introduction Evidence supports clozapine as the best treatment in terms of efficacy, effectiveness and well-being, and as the gold standard in treatment-resistant psychotic disorders. Clozapine remains still underused, suffering initiation delays from 1.
L.I. Muñoz-Manchado   +7 more
doaj   +1 more source

Clozapine treatment during the COVID-19 pandemic

open access: yesEuropean Psychiatry, 2021
Introduction Clozapine is an effective antipsychotic used in treatment-resistant schizophrenia. One of the serious complications of clozapine therapy is agranulocytosis, therefore regular monitoring of the level of white blood cells (WBC) in plasma is ...
E. Dąbrowska   +3 more
doaj   +1 more source

Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review

open access: yes, 2023
Clozapine-induced myocarditis in children (age ≤18 yo) was studied from a PubMed search (18 July 2022) (9 cases) and from the World Health Organization’s pharmacovigilance database, called Vigibase, of adverse drug reaction (ADR) reports (72 non ...
Jose de Leon (4242862)   +5 more
core   +1 more source

Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation

open access: yesTherapeutic Advances in Psychopharmacology, 2020
Background: Clozapine formulation has been shown to affect plasma concentrations of clozapine and norclozapine. Changes in formulation might result in toxicity or treatment failure.
Farinaz Keshavarzi   +3 more
doaj   +1 more source

Factors predicting serum clozapine levels in Middle Eastern patients: an observational study

open access: yesBMC Psychiatry, 2022
Background Despite its superiority over other drugs for psychosis, clozapine remains underused and is associated with many clinical challenges, including difficulties in predicting therapeutic serum levels (350-600 ng/mL).
Ahmed Hassab Errasoul   +1 more
doaj   +1 more source

Setting up a clozapine service for Parkinson's psychosis

open access: yes, 2021
Parkinson's psychosis can be very challenging to manage, with limited treatment options available. There is a good evidence base to support the use of clozapine, but practical obstacles often prevent its use.
Marsh-Davies, Alison   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy